drugset / Trial / NCT00895297
Efficacy and Safety Study of Dasatinib in Patients With Chronic Myeloid Leukemia
Phase 2
Terminated
50 enrolled
European Society for Blood and Marrow Transplantation
Bristol-Myers Squibb · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a phase II efficacy (indicates the capacity for beneficial change or therapeutic effect) and safety study of Dasatinib in patients with relapsed Chronic Myeloid Leukemia (CML) following a Stem Cell Transplant (SCT) and who are not benefiting from other treatment, such as imatinib therapy. A relapse is when an illness that has seemed to be getting better, or to have been cured, comes back or gets worse again. A total of 50 patients ≥18 years of age will be registered on the trial.
Timeline
- Start
- 2010-02
- Primary completion
- 2011-10
- Completion
- 2011-11
Outcome
Outcome not reported
Stopped (Enrollment): “Slow recruitment. No safety concerns during this study.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | dasatinib anhydrous | Small molecule | 100 mg | Oral |